Li-Xuan Qin

Associate Attending Biostatistician

Share
Print
Share
Print
Li-Xuan Qin

Office Phone

646-888-8251

Education

University of Washington

Current Research Interests

Dr. Qin develops benchmark data, analytic methods, and computational tools for enabling reproducible statistical translations of cancer genomics data. With colleagues at Memorial Sloan Kettering, she has designed and collected unique benchmark datasets to study the issue of data normalization (i.e. ‘treatment’ for data artifacts due to disparate collection) for microarrays and sequencing. She has developed novel simulation procedures and software packages to show that normalization can lead to seemingly optimistic classifiers, due to its ‘side-effect’ of over-compressed data variability. She is studying the impact of its ‘off-label’ use for an otherwise unapproved inference goal such as tumor subtyping and survival prediction. She has established an improved stochastic distribution for modeling sequencing data and is examining its implication on data normalization. Her research program is supported by a previous NIH R01 grant and an ongoing NIH R21 grant. Dr. Qin collaborates primarily with multidisciplinary investigators (Surgery, Medicine, Radiation Oncology, Pathology, and Radiology) engaged in research on sarcoma, for design and analysis of retrospective and prospective studies. She serves as co-Director of the Biostatistics and Bioinformatics Core on the Soft Tissue Sarcoma SPORE. Over the years she has also worked with investigators studying the molecular basis of other cancer types such as breast, ovarian, and pancreatic cancer. Dr. Qin has recently served as Statistical Reviewer for the Protocol Development Committee of the Department of Medicine, assessing investigator-initiated protocols for statistical rigor. She currently serves as a member of Research Council, which reviews investigator-initiated and industry-sponsored protocols for scientific merit and priority.

Publications

  1. Qin LX and Self SG. The clustering of regression models method with applications to gene expression data. Biometrics 2006, 62:526-533.
  2. Qin LX, Zhou Q, Bogomolniy F, Villafania L, Olvera N, Cavatore M, Satagopan JM, Begg CB, Levine DA. Blocking and randomization to improve molecular biomarker discovery. Clinical Cancer Research 2014, 20:3371-3378.
  3. Qin LX, Levine DA. Study design and data normalization to improve the discovery of prognostic molecular biomarkers. BMC Medical Genomics 2016, 9:27.
  4. Qin LX, Huang HC, Begg CB. Cautionary note on using cross-validation for molecular classification. Journal of Clinical Oncology 2016, Epub ahead of print.
  5. Qin LX, Tuschl T, Singer S. Empirical insights into the stochasticity of small RNA sequencing. Scientific Reports 2016, 6:24061.

Visit PubMed for a full listing of Li-Xuan Qin’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Li-Xuan Qin discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures